The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Alisertib in patients with extensive-stage small-cell lung cancer: The phase 2 ALISCA-Lung1 study.
 
Taofeek K. Owonikoko
Stock and Other Ownership Interests - CAMBIUM MEDICAL TECHNOLOGIES; Coherus Biosciences; GenCart; Taobob LLC
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; BeiGene; BerGenBio; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Coherus Biosciences; Daichi; Eisai; Eisai; EMD Serono; Exelixis; G1 Therapeutics; Heat Biologics; Ipsen; Janssen; Jazz Pharmaceuticals; Lilly; MedImmune; Merck; Meryx Pharmaceuticals; Novartis; PharmaMar; Puma Biotechnology; Roche/Genentech; Takeda; Triptych Health Partners; Xcovery
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Corvus Pharmaceuticals; G1 Therapeutics (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Loxo/Lilly (Inst); Merck (Inst); Meryx Pharmaceuticals (Inst); Novartis (Inst); Oncorus (Inst); Pfizer (Inst); Regeneron (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - DR4 Modulation and its Implications in EGFR-Target Cancer Therapy Ref:18089 PROV (CSP) United States Patent Application No. 62/670,210 June 26, 2018 (Co-Inventor) (Inst); OVERCOMING ACQUIRED RESISTANCE TO CHEMOTHERAPY TREATMENTS THROUGH SUPPRESSION OF STAT3 (Inst); SELECTIVE CHEMOTHERAPY TREATMENTS AND DIAGNOSTIC METHODS RELATED THERETO (Inst); Soluble FAS ligand as a biomarker of recurrence in thyroid cancer; provisional patent 61/727,519 (Inventor) (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Janssen
Other Relationship - EMD Serono; Novartis; Roche/Genentech
(OPTIONAL) Uncompensated Relationships - Reflexion Medical
 
Alberto Chiappori
Stock and Other Ownership Interests - Merck
Consulting or Advisory Role - Ailleron; Amgen; Daiichi Sankyo/Lilly; G1 Therapeutics; Jazz Pharmaceuticals; Merus; Mirati Therapeutics; Sanofi/Regeneron
Speakers' Bureau - Amgen; Blueprint Medicines; Genentech; Takeda
Research Funding - AstraZeneca; Bristol-Myers Squibb; Jazz Pharmaceuticals
Travel, Accommodations, Expenses - Amgen; Takeda
 
Ryan D. Gentzler
Honoraria - Aptitude Health; Clinical Care Options; OncLive
Consulting or Advisory Role - AstraZeneca; Gilead Sciences; Janssen; Merus; Regeneron; Takeda
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dizal Pharma; Janssen (Inst); Jounce Therapeutics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); RTI International (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Tempus
 
Stephen V. Liu
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Candel Therapeutics; Catalyst Pharmaceuticals; Daiichi Sankyo/UCB Japan; Elevation Oncology; Genentech; Gilead Sciences; Guardant Health; Janssen Oncology; Jazz Pharmaceuticals; Merus; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; RAPT Therapeutics; Regeneron; Revolution Medicines; Sanofi; Takeda
Research Funding - Abbvie (Inst); Alkermes (Inst); Elevation Oncology (Inst); Ellipses Pharma (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Merck (Inst); Merus (Inst); Nuvalent, Inc. (Inst); OSE Immunotherapeutics (Inst); Puma Biotechnology (Inst); RAPT Therapeutics (Inst); Turning Point Therapeutics (Inst)
 
Adedayo A. Onitilo
No Relationships to Disclose
 
Nathan A. Pennell
Consulting or Advisory Role - Anheart Therapeutics; Bayer; Genentech; Iovance Biotherapeutics; Janssen Oncology; Lilly; Merck; Novartis; Pfizer; Picture Health; ResistanceBio; Sanofi/Regeneron; Summit Therapeutics; Takeda; Vial
Research Funding - Anheart Therapeutics (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Loxo (Inst); Merck (Inst); Mirati Therapeutics (Inst); Navire (Inst); Sanofi (Inst); Spectrum Pharmaceuticals (Inst); Summit pharmaceuticals (Inst)
 
Jacob Sands
Honoraria - Pfizer
Consulting or Advisory Role - Abbvie; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo/UCB Japan; G1 Therapeutics; Gilead Sciences; Guardant Health; Lilly; Medtronic; PharmaMar; Sanofi
Research Funding - Amgen; Harpoon
Travel, Accommodations, Expenses - AstraZeneca
 
Bo Wang
Consulting or Advisory Role - AstraZeneca; Castle Biosciences; EMD Serono; Guardant Health; Sanofi
Speakers' Bureau - EMD Serono; Sanofi
 
Beth Hillary Lowenthal
Employment - Puma Biotechnology
Stock and Other Ownership Interests - Puma Biotechnology
 
Judith D. Bebchuk
Employment - Puma Biotechnology
Stock and Other Ownership Interests - Puma Biotechnology
 
Lisa DeFazio Eli
Employment - Puma Biotechnology
Stock and Other Ownership Interests - Puma Biotechnology
 
Elaine K. Wong
Consulting or Advisory Role - Myovant Sciences; Nested Therapeutics; Puma Biotechnology; Sarah Cannon Research Institute
Travel, Accommodations, Expenses - Puma Biotechnology
 
Afshin Dowlati
Consulting or Advisory Role - Abbvie/Stemcentrx; AstraZeneca; Bristol-Myers Squibb; Ipsen; Merck; Tempus
Research Funding - Abbvie/Stemcentrx (Inst); Amgen (Inst); Astellas Pharma (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); Bristol-Myers Squibb (Inst); Coordination Pharmaceuticals (Inst); Gilead Sciences (Inst); Ipsen (Inst); Lilly/ImClone (Inst); Mirati Therapeutics (Inst); Pionyr (Inst); Seagen (Inst); Takeda (Inst); Tesaro (Inst)